Increased cyclin T1 expression as a favorable prognostic factor in treating gastric adenocarcinoma

Jin,Jong‑Shiaw; Lin,Lien‑Fu; Chen,Jui‑Chang; Huang,Chia‑Chi; Sheu,Jeng‑Horng; Chen,Wenlung; Tsao,Tang‑Yi; Hsu,Chih‑Wei

doi:10.3892/ol.2015.3749

Increased cyclin T1 expression as a favorable prognostic factor in treating gastric adenocarcinoma

Authors:
- Jong‑Shiaw Jin
- Lien‑Fu Lin
- Jui‑Chang Chen
- Chia‑Chi Huang
- Jeng‑Horng Sheu
- Wenlung Chen
- Tang‑Yi Tsao
- Chih‑Wei Hsu
View Affiliations

Affiliations: Department of Pathology, Tungs' Taichung Metro Harbor Hospital, Taichung 43503, Taiwan, R.O.C., Division of Gastroenterology, Department of Internal Medicine, Tungs' Taichung Metro Harbor Hospital, Taichung 43503, Taiwan, R.O.C., Department of Applied Chemistry, National Chiayi University, Chia‑Yi 60004, Taiwan, R.O.C., Center of Nano Bio‑detection, National Chung Cheng University, Chia‑Yi 62102, Taiwan, R.O.C., Division of General Surgery, Department of Surgery, Tungs' Taichung Metro Harbor Hospital, Taichung 43503, Taiwan, R.O.C.
Published online on: September 25, 2015 https://doi.org/10.3892/ol.2015.3749
Pages: 3712-3718

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of cyclin A, B1, D1 and E in gastric adenocarcinoma is known to be associated with clinical outcome. However, few studies have investigated the role of cyclin T1 and cyclin‑dependent kinase 9 (CDK9) in gastric adenocarcinoma. Therefore, this study assessed the clinical significance of cyclin T1 and CDK9 expression in gastric adenocarcinoma. A total of 39 gastric adenocarcinoma patients received either radical total or distal gastrectomy in this study. Surgical tissue slides were stained with CDK9 and cyclin T1 antibodies, and immunohistochemistry scores and disease‑free survival (DFS) rates were analyzed. Among the 19 patients with tumor‑recurrent or distant metastasis, 16 were recorded as exhibiting low expression of cyclin T1. The remaining three patients exhibited high expression of the antibody. The results of patients with a higher T stage, N stage and tumor grade were less favorable. For patients with adenocarcinoma, the percentage of tissue slides stained with cyclin T1 was significantly higher than for those with normal stomach epithelia. The DFS rates of patients with low expression of cyclin T1 were significantly associated with poorer DFS rates. In conclusion, high expression of cyclin T1 is a favorable prognostic factor in treating patients with stomach adenocarcinoma.

View Figures

View References

1	Ferlay J, Bray F, Pisani P and Parkin M: GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press. 2004.
2	Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H and Kelsen DP: Molecular classification of gastric cancer: a new paradigm. Clin Cancer Res. 17:2693–2701. 2011. View Article : Google Scholar : PubMed/NCBI
3	Moiola C, De Luca P, Gardner K, Vazquez E and De Siervi A: Cyclin T1 overexpression induces malignant transformation and tumor growth. Cell Cycle. 9:3119–3126. 2010. View Article : Google Scholar : PubMed/NCBI
4	De Luca A, De Falco M, Baldi A and Paggi MG: Cyclin T: three forms for different roles in physiological and pathological functions. J Cell Physiol. 194:101–107. 2003. View Article : Google Scholar : PubMed/NCBI
5	De Luca A, Russo P, Severino A, Baldi A, Battista T, Cavallotti I, De Luca L, Baldi F, Giordano A and Paggi MG: Pattern of expression of cyclin T1 in human tissues. J Histochem Cytochem. 49:685–692. 2001. View Article : Google Scholar : PubMed/NCBI
6	Sano M and Schneider MD: Cyclin-dependent kinase-9: an RNAPII kinase at the nexus of cardiac growth and death cascades. Circ Res. 95:867–876. 2004. View Article : Google Scholar : PubMed/NCBI
7	Sano M, Wang SC, Shirai M, Scaglia F, Xie M, Sakai S, Tanaka T, Kulkarni PA, Barger PM, Youker KA, et al: Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. EMBO J. 23:3559–3569. 2004. View Article : Google Scholar : PubMed/NCBI
8	Chiu YL, Cao H, Jacque JM, Stevenson M and Rana TM: Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). J Virol. 78:2517–2529. 2004. View Article : Google Scholar : PubMed/NCBI
9	Chao SH and Price DH: Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem. 276:31793–31799. 2001. View Article : Google Scholar : PubMed/NCBI
10	Napolitano G, Majello B and Lania L: Role of cyclinT/Cdk9 complex in basal and regulated transcription (review). Int J Oncol. 21:171–177. 2002.PubMed/NCBI
11	Chen R, Keating MJ, Gandhi V and Plunkett W: Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 106:2513–2519. 2005. View Article : Google Scholar : PubMed/NCBI
12	Shan B, Zhuo Y, Chin D, Morris CA, Morris GF and Lasky JA: Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells. J Biol Chem. 280:1103–1011. 2005. View Article : Google Scholar : PubMed/NCBI
13	Sugai T, Tsukahara M, Endoh M, Shioi Y, Takebe N, Mue Y, Matsushita H, Toyota M and Suzuki K: Analysis of cell cycle-related proteins in gastric intramucosal differentiated-type cancers based on mucin phenotypes: a novel hypothesis of early gastric carcinogenesis based on mucin phenotype. BMC Gastroenterol. 10:552010. View Article : Google Scholar : PubMed/NCBI
14	Ioachim E: Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features. Int J Clin Pract. 62:1736–1743. 2008. View Article : Google Scholar : PubMed/NCBI
15	Motohashi M, Wakui S, Muto T, Suzuki Y, Shirai M, Takahashi H and Hano H: Cyclin D1/cdk4, estrogen receptors α and β, in N-methyl-N'-nitro-N-nitrosoguanidine-induced rat gastric carcinogenesis: immunohistochemical study. J Toxicol Sci. 36:373–378. 2011. View Article : Google Scholar : PubMed/NCBI
16	Kouraklis G, Katsoulis IE, Theocharis S, Tsourouflis G, Xipolitas N, Glinavou A, Sioka C and Kostakis A: Does the expression of cyclin E, pRb and p21 correlate with prognosis in gastric adenocarcinoma? Dig Dis Sci. 54:1015–1020. 2009. View Article : Google Scholar : PubMed/NCBI
17	Li JQ, Miki H, Wu F, Saoo K, Nishioka M, Ohmori M and Imaida K: Cyclin A correlates with carcinogenesis and metastasis and p27(kip1) correlates with lymphatic invasion, in colorectal neoplasms. Hum Pathol. 33:1006–1015. 2002. View Article : Google Scholar : PubMed/NCBI
18	Mrena J, Wiksten JP, Kokkola A, Nordling S, Haglund C and Ristimäki A: Prognostic significance of cyclin A in gastric cancer. Int J Cancer. 119:1897–1901. 2006. View Article : Google Scholar : PubMed/NCBI
19	Yasuda M, Takesue F, Inutsuka S, Honda M, Nozoe T and Korenaga D: Overexpression of cyclin B1 in gastric cancer and its clinicopathological significance: an immunohistological study. J Cancer Res Clin Oncol. 128:412–416. 2002. View Article : Google Scholar : PubMed/NCBI
20	Washington K: 7th edition of the AJCC cancer staging manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010. View Article : Google Scholar : PubMed/NCBI
21	Berlth F, Bollschweiler E, Drebber U, Hoelscher AH and Moenig S: Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value. World J Gastroenterol. 20:5679–5684. 2014. View Article : Google Scholar : PubMed/NCBI
22	Leucci E, De Falco G, Onnis A, Cerino G, Cocco M, Luzzi A, Crupi D, Tigli C, Bellan C, Tosi P, et al: The role of the Cdk9/Cyclin T1 complex in T cell differentiation. J Cell Physiol. 212:411–415. 2007. View Article : Google Scholar : PubMed/NCBI
23	Bellan C, De Falco G, Lazzi S, Micheli P, Vicidomini S, Schürfeld K, Amato T, Palumbo A, Bagella L, Sabattini E, et al: CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation. J Pathol. 203:946–952. 2004. View Article : Google Scholar : PubMed/NCBI
24	MacLachlan TK, Sang N, De Luca A, Puri PL, Levrero M and Giordano A: Binding of CDK9 to TRAF2. J Cell Biochem. 71:467–478. 1998. View Article : Google Scholar : PubMed/NCBI
25	Fu TJ, Peng J, Lee G, Price DH and Flores O: Cyclin K functions as a CDK9 regulatory subunit and participates in RNA polymerase II transcription. J Biol Chem. 274:34527–34530. 1999. View Article : Google Scholar : PubMed/NCBI
26	Bettayeb K, Tirado OM, Marionneau-Lambot S, Ferandin Y, Lozach O, Morris JC, Mateo-Lozano S, Drueckes P, Schächtele C, Kubbutat MH, et al: Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res. 67:8325–8334. 2007. View Article : Google Scholar : PubMed/NCBI
27	De Falco G and Giordano A: CDK9: From basal transcription to cancer and AIDS. Cancer Biol Ther. 1:342–377. 2002. View Article : Google Scholar : PubMed/NCBI
28	Lee DK, Duan HO and Chang C: Androgen receptor interacts with the positive elongation factor P-TEFb and enhances the efficiency of transcriptional elongation. J Biol Chem. 276:9978–9984. 2001. View Article : Google Scholar : PubMed/NCBI
29	Peng J, Zhu Y, Milton JT and Price DH: Identification of multiple cyclin subunits of human P-TEFb. Genes Dev. 12:755–762. 1998. View Article : Google Scholar : PubMed/NCBI
30	Napolitano G, Majello B, Licciardo P, Giordano A and Lania L: Transcriptional activity of positive transcription elongation factor b kinase in vivo requires the C-terminal domain of RNA polymerase II. Gene. 254:139–145. 2000. View Article : Google Scholar : PubMed/NCBI
31	Garriga J, Peng J, Parreño M, Price DH, Henderson EE and Graña X: Upregulation of cyclin T1/CDK9 complexes during T cell activation. Oncogene. 17:3093–3102. 1998. View Article : Google Scholar : PubMed/NCBI